{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:56:07Z","timestamp":1792151767675,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS119183"],"award-info":[{"award-number":["R01NS119183"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS141861"],"award-info":[{"award-number":["R01NS141861"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R35CA197264"],"award-info":[{"award-number":["R35CA197264"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA154291"],"award-info":[{"award-number":["P01CA154291"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-026-04715-w","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:29:48Z","timestamp":1792150188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EGFR-targeted antibody\u2212toxin conjugate in recurrent glioma: a phase 1 trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0653-3014","authenticated-orcid":false,"given":"Vidyalakshmi","family":"Chandramohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James E.","family":"Herndon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-8444","authenticated-orcid":false,"given":"Anjali","family":"Barnwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Ayasoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6082-9326","authenticated-orcid":false,"given":"Weixuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1727-3032","authenticated-orcid":false,"given":"Michelle L.","family":"Bowie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1164","authenticated-orcid":false,"given":"Michael C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-1912","authenticated-orcid":false,"given":"Smita K.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-0302","authenticated-orcid":false,"given":"Matthias","family":"Gromeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3394-656X","authenticated-orcid":false,"given":"Dina","family":"Randazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret O.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-4588","authenticated-orcid":false,"given":"Roger E.","family":"McLendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-1136","authenticated-orcid":false,"given":"Daniel","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9223-0270","authenticated-orcid":false,"given":"Ira H.","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-032X","authenticated-orcid":false,"given":"Henry S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4754-5900","authenticated-orcid":false,"given":"David M.","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darell D.","family":"Bigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-8283","authenticated-orcid":false,"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"4715_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u22122020. Neuro Oncol. 25, iv1\u2013iv99 (2023).","journal-title":"Neuro Oncol."},{"key":"4715_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"4715_CR3","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp, R. et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314, 2535\u20132543 (2015).","journal-title":"JAMA"},{"key":"4715_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","volume":"15","author":"W Taal","year":"2014","unstructured":"Taal, W. et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 15, 943\u2013953 (2014).","journal-title":"Lancet Oncol."},{"key":"4715_CR5","doi-asserted-by":"crossref","unstructured":"Cruz Da Silva, E., Mercier, M. C., Etienne-Selloum, N., Dontenwill, M. & Choulier, L. A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers (Basel) 13, 1795 (2021).","DOI":"10.3390\/cancers13081795"},{"key":"4715_CR6","first-page":"753","volume":"44","author":"TA Libermann","year":"1984","unstructured":"Libermann, T. A. et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 44, 753\u2013760 (1984).","journal-title":"Cancer Res."},{"key":"4715_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"4715_CR8","first-page":"1383","volume":"60","author":"L Frederick","year":"2000","unstructured":"Frederick, L., Wang, X. Y., Eley, G. & James, C. D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60, 1383\u20131387 (2000).","journal-title":"Cancer Res."},{"key":"4715_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807\u20131812 (2008).","journal-title":"Science"},{"key":"4715_CR10","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-12-3891","volume":"19","author":"V Chandramohan","year":"2013","unstructured":"Chandramohan, V. et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin. Cancer Res. 19, 4717\u20134727 (2013).","journal-title":"Clin. Cancer Res."},{"key":"4715_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.nucmedbio.2011.06.005","volume":"39","author":"MR Zalutsky","year":"2012","unstructured":"Zalutsky, M. R. et al. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl. Med. Biol. 39, 23\u201334 (2012).","journal-title":"Nucl. Med. Biol."},{"key":"4715_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","volume":"15","author":"WA Banks","year":"2016","unstructured":"Banks, W. A. From blood\u2212brain barrier to blood\u2212brain interface: new opportunities for CNS drug delivery. Nat. Rev. Drug Discov. 15, 275\u2013292 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4715_CR13","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1073\/pnas.91.6.2076","volume":"91","author":"RH Bobo","year":"1994","unstructured":"Bobo, R. H. et al. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl Acad. Sci. USA 91, 2076\u20132080 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4715_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1215\/15228517-2008-012","volume":"10","author":"JH Sampson","year":"2008","unstructured":"Sampson, J. H. et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 10, 320\u2013329 (2008).","journal-title":"Neuro Oncol."},{"key":"4715_CR15","doi-asserted-by":"crossref","unstructured":"Ezzati, S., Salib, S., Balasubramaniam, M. & Aboud, O. Epidermal growth factor receptor inhibitors in glioblastoma: current status and future possibilities. Int. J. Mol. Sci. 25, 2316 (2024).","DOI":"10.3390\/ijms25042316"},{"key":"4715_CR16","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","volume":"23","author":"BM Marin","year":"2021","unstructured":"Marin, B. M. et al. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro Oncol. 23, 2042\u20132053 (2021).","journal-title":"Neuro Oncol."},{"key":"4715_CR17","volume":"4","author":"KA Porath","year":"2022","unstructured":"Porath, K. A. et al. Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts. Neurooncol. Adv. 4, vdac130 (2022).","journal-title":"Neurooncol. Adv."},{"key":"4715_CR18","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1007\/s00253-016-8063-x","volume":"101","author":"V Chandramohan","year":"2017","unstructured":"Chandramohan, V. et al. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I\/II clinical trial. Appl. Microbiol. Biotechnol. 101, 2747\u20132766 (2017).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"4715_CR19","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","volume":"28","author":"JH Sampson","year":"2010","unstructured":"Sampson, J. H. et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722\u20134729 (2010).","journal-title":"J. Clin. Oncol."},{"key":"4715_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865 (2021).","journal-title":"Cancer Cell"},{"key":"4715_CR21","doi-asserted-by":"publisher","first-page":"e0197743","DOI":"10.1371\/journal.pone.0197743","volume":"13","author":"M Khunger","year":"2018","unstructured":"Khunger, M. et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS ONE 13, e0197743 (2018).","journal-title":"PLoS ONE"},{"key":"4715_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8628540","volume":"2020","author":"E Topkan","year":"2020","unstructured":"Topkan, E. et al. Systemic inflammation response index predicts survival outcomes in glioblastoma multiforme patients treated with standard Stupp protocol. J. Immunol. Res. 2020, 8628540 (2020).","journal-title":"J. Immunol. Res."},{"key":"4715_CR23","doi-asserted-by":"crossref","unstructured":"Azzouz, D. & Palaniyar, N. How do ROS induce NETosis? Oxidative DNA damage, DNA repair, and chromatin decondensation. Biomolecules 14, 1307 (2024).","DOI":"10.3390\/biom14101307"},{"key":"4715_CR24","doi-asserted-by":"crossref","unstructured":"Silva, B.M. et al. C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps. J. Clin. Invest. 133, e163105 (2023).","DOI":"10.1172\/JCI163105"},{"key":"4715_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3171\/2009.11.JNS091052","volume":"113","author":"JH Sampson","year":"2010","unstructured":"Sampson, J. H. et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J. Neurosurg. 113, 301\u2013309 (2010).","journal-title":"J. Neurosurg."},{"key":"4715_CR26","doi-asserted-by":"crossref","unstructured":"Brady, M., Raghavan, R. & Sampson, J. Determinants of intraparenchymal infusion distributions: modeling and analyses of human glioblastoma trials. Pharmaceutics 12, 895 (2020).","DOI":"10.3390\/pharmaceutics12090895"},{"key":"4715_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins, A. et al. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med. 379, 150\u2013161 (2018).","journal-title":"N. Engl. J. Med."},{"key":"4715_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11060-025-05282-9","volume":"176","author":"K Samimi","year":"2025","unstructured":"Samimi, K., Saini, A. S., Cullison, K., Herr, J. & Mellon, E. A. EGFR pathway alterations correlate with rapid early progression in glioblastoma. J. Neurooncol. 176, 77 (2025).","journal-title":"J. Neurooncol."},{"key":"4715_CR29","doi-asserted-by":"publisher","first-page":"1236246","DOI":"10.3389\/fonc.2023.1236246","volume":"13","author":"XP Li","year":"2023","unstructured":"Li, X. P., Guo, Z. Q., Wang, B. F. & Zhao, M. EGFR alterations in glioblastoma play a role in antitumor immunity regulation. Front. Oncol. 13, 1236246 (2023).","journal-title":"Front. Oncol."},{"key":"4715_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-019-0614-0","volume":"7","author":"V Chandramohan","year":"2019","unstructured":"Chandramohan, V. et al. Improved efficacy against malignant brain tumors with EGFRwt\/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J. Immunother. Cancer 7, 142 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"4715_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn5649","volume":"15","author":"S Parker","year":"2023","unstructured":"Parker, S. et al. Immunotoxin-\u03b1CD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Sci. Transl. Med. 15, eabn5649 (2023).","journal-title":"Sci. Transl. Med."},{"key":"4715_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1535-7163.MCT-15-0901","volume":"15","author":"AC Phillips","year":"2016","unstructured":"Phillips, A. C. et al. ABT-414, an antibody\u2212drug conjugate targeting a tumor-selective EGFR epitope. Mol. Cancer Ther. 15, 661\u2013669 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"4715_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman, A. B. et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 25, 339\u2013350 (2023).","journal-title":"Neuro Oncol."},{"key":"4715_CR34","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/neuonc\/noz222","volume":"22","author":"M Van Den Bent","year":"2020","unstructured":"Van Den Bent, M. et al. INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 22, 684\u2013693 (2020).","journal-title":"Neuro Oncol."},{"key":"4715_CR35","volume":"3","author":"HK Gan","year":"2021","unstructured":"Gan, H. K. et al. Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. Neurooncol. Adv. 3, vdab102 (2021).","journal-title":"Neurooncol. Adv."},{"key":"4715_CR36","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"4715_CR37","unstructured":"Urbaniak, G.C. & Pious, S. Research Randomizer (version 4.0) https:\/\/randomizer.org (2013)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04715-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04715-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04715-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:29:50Z","timestamp":1792150190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04715-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":37,"alternative-id":["4715"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04715-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.C., I.H.P. and D.D.B. are inventors of ATC patent applications. A.D. serves as an advisory board member for Orbus Therapeutics, Telix Therapeutics and Altido and receives clinical research support (to the institution) from Orbus Therapeutics, Exvade Bioscience, Creosalus and Biodexa. D.M.A. serves as an advisory board member for Immunogenesis, MAIA Biotechnology and Diverse Biotech and as a consultant for The Jackson Laboratory. K.B.P. serves as an advisory board member for Servier, Rigel Pharmaceuticals and Nuvation Bio and receives clinical research support (to the institution) from Servier, Nuvation Bio, Curis, Deciphera, Ono Pharmaceutical and Novocure. J.H.S. serves as a member of the Board of Directors of Labcorp. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}